nach oben

vorheriger Artikel ASH 2011—current developments in AML

nächster Artikel Paraneoplastic neurologic disorders: a brief ov...

Tipp

Primary central nervous system lymphoma: update and current approach

Zeitschrift:: memo - Magazine of European Medical Oncology > Ausgabe 3/2012

Autor:: M.D. Lauren E. Abrey

Abstract

Primary central nervous system lymphoma (PCNSL) is a rare type of lymphoma that requires a specialised approach to management. An initial evaluation should determine the extent of disease within the CNS compartment and must exclude the presence of systemic lymphoma. Methotrexate (MTX)-based chemotherapy is the standard of care but questions remain about the optimal drugs for use in conjunction with MTX as well as the best approach to consolidation. Furthermore, several special populations may require a modified approach to therapy.

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Jetzt einloggen Kostenlos registrieren

Sie möchten Zugang zu diesem Inhalt erhalten? Dann informieren Sie sich jetzt über unsere Produkte:

Abo für kostenpflichtige Inhalte

Jetzt informieren

Deckert M, Engert A, Brück W, et al. Modern concepts in the biology, diagnosis, differential diagnosis and treatment of primary central nervous system lymphoma. Leukemia. 2011;25(12):1797–807. PubMedCrossRef

Morris PG, Abrey LE. Therapeutic challenges in primary CNS lymphoma. Lancet Neurol. 2009;8:581–92. PubMedCrossRef

Schroers R, Baraniskin A, Heute C, et al. Diagnosis of leptomeningeal disease in diffuse large B-cell lymphomas of the central nervous system by flow cytometry and cytopathology. Eur J Haematol. 2010;85(6):520–8. PubMedCrossRef

Hegde U, Filie A, Little RF, et al. High incidence of occult leptomeningeal disease detected by flow cytometry in newly diagnosed aggressive B-cell lymphomas at risk for central nervous system involvement: the role of flow cytometry versus cytology. Blood. 2005;105(2):496–502. PubMedCrossRef

Abrey LE, Batchelor TT, Ferreri AJ, et al. Report of an international workshop to standardize baseline evaluation and response criteria for primary CNS lymphoma. J Clin Oncol. 2005;23(22):5034–43. PubMedCrossRef

Mohile NA, Deangelis LM, Abrey LE. The utility of body FDG PET in staging primary central nervous system lymphoma. Neuro Oncol. 2008;10(2):223–8. PubMedCrossRef

Vassal G, Valteau D, Bonnay M, Patte C, Aubier F, Lemerle J. Cerebrospinal fluid and plasma methotrexate levels following high-dose regimen given as a 3-hour intravenous infusion in children with non Hodgkin’s lymphoma. Pediatr Hematol Oncol. 1990;7:71–7. PubMedCrossRef

Ferreri AJ, Reni M, Pasini F, et al. A multicenter study of treatment of primary CNS lymphoma. Neurology. 2002;58(10):1513–20. PubMedCrossRef

Ferreri AJ, Reni M, Foppoli M, et al. High-dose cytarabine plus high-dose methotrexate versus high-dose methotrexate alone in patients with primary CNS lymphoma: a randomised phase 2 trial. Lancet. 2009;374(9700):1512–20. PubMedCrossRef

10.

Ferreri AJ, Licata G, Foppoli M, et al. Clinical relevance of the dose of cytarabine in the upfront treatment of primary CNS lymphomas with methotrexate-cytarabine combination. Oncologist. 2011;16(3):336–41. PubMedCrossRef

11.

Juergens A, Pels H, Rogowski S, et al. Long-term survival with favorable cognitive outcome after chemotherapy in primary central nervous system lymphoma. Ann Neurol. 2010;67(2):182–9. PubMedCrossRef

12.

Pels H, Juergens A, Glasmacher A, et al. Early relapses in primary CNS lymphoma after response to polychemotherapy without intraventricular treatment: results of a phase II study. J Neurooncol. 2009;91(3):299–305. PubMedCrossRef

13.

Khan RB, Shi W, Thaler TH, DeAngelis LM, Abrey LE. Is intrathecal methotrexate necessary in the treatment of primary CNS lymphoma? J Neurooncol. 2002;58:175–78. PubMedCrossRef

14.

National Comprehensive Cancer Network: Oncology practice guidelines, version 1.2012; central nervous system cancers. 2012. http://www.nccn.org/professionals/physician_gls/pdf/cns.pdf. Accessed 30 April 2012.

15.

Soussain C, Hoang-Xuan K, Taillandier L, et al. Intensive chemotherapy followed by hematopoietic stem-cell rescue for refractory and recurrent primary CNS and intraocular lymphoma: Société Française de Greffe de Moëlle Osseuse-Thérapie Cellulaire. J Clin Oncol. 2008;26(15):2512–8. PubMedCrossRef

16.

Kasenda B, Schorb E, Fritsch K, Finke J, Illerhaus G. Prognosis after high-dose chemotherapy followed by autologous stem-cell transplantation as first-line treatment in primary CNS lymphoma—a long-term follow-up study. Ann Oncol. 2012 Apr 3. Epub ahead of print.

17.

Wieduwilt MJ, Valles F, Issa S, et al. Immunochemotherapy with intensive consolidation for primary CNS lymphoma: a pilot study and prognostic assessment by diffusion-weighted MRI. Clin Cancer Res. 2012;18(4):1146–55. PubMedCrossRef

18.

Batchelor TT, Grossman SA, Mikkelsen T, et al. Rituximab monotherapy for patients with recurrent primary CNS lymphoma. Neurology. 2011;76(10):929–30. PubMedCrossRef

19.

Fritsch K, Kasenda B, Hader C, et al. Immunochemotherapy with rituximab, methotrexate, procarbazine, and lomustine for primary CNS lymphoma (PCNSL) in the elderly. Ann Oncol. 2011;22(9):2080–5. PubMedCrossRef

20.

Shah GD, Yahalom J, Correa DD, et al. Combined immunochemotherapy with reduced whole-brain radiotherapy for newly diagnosed primary CNS lymphoma. J Clin Oncol. 2007;25(30):4730–5. PubMedCrossRef

21.

Villa D, Connors JM, Shenkier TN, Gascoyne RD, Sehn LH, Savage KJ. Incidence and risk factors for central nervous system relapse in patients with diffuse large B-cell lymphoma: the impact of the addition of rituximab to CHOP chemotherapy. Ann Oncol. 2010;21(5):1046–52. PubMedCrossRef

22.

Thiel E, Korfel A, Martus P, et al. High-dose methotrexate with or without whole brain radiotherapy for primary CNS lymphoma (G-PCNSL-SG-1): a phase 3, randomised, non-inferiority trial. Lancet Oncol. 2010;11(11):1036–47. PubMedCrossRef

23.

Bessell EM, López-Guillermo A, Villá S, et al. Importance of radiotherapy in the outcome of patients with primary CNS lymphoma: an analysis of the CHOD/BVAM regimen followed by two different radiotherapy treatments. J Clin Oncol. 2002;20(1):231–6. PubMedCrossRef

24.

Omuro A, Taillandier L, Chinot O, et al. Primary CNS lymphoma in patients younger than 60: can whole-brain radiotherapy be deferred? J Neurooncol. 2011;104(1):323–30. PubMedCrossRef

25.

Villano JL, Koshy M, Shaikh H, Dolecek TA, McCarthy BJ. Age, gender, and racial differences in incidence and survival in primary CNS lymphoma. Br J Cancer. 2011;105(9):1414–8. PubMedCrossRef

26.

Zhu JJ, Gerstner ER, Engler DA, et al. High-dose methotrexate for elderly patients with primary CNS lymphoma. Neuro Oncol. 2009;11(2):211–5. PubMedCrossRef

27.

Ney DE, Reiner AS, Panageas KS, Brown HS, Deangelis LM, Abrey LE. Characteristics and outcomes of elderly patients with primary central nervous system lymphoma: the Memorial Sloan-Kettering Cancer Center experience. Cancer 2010;116:4605–12. PubMedCrossRef

28.

Omuro AM, Taillandier L, Chinot O, Carnin C, Barrie M, Hoang-Xuan K. Temozolomide and methotrexate for primary central nervous system lymphoma in the elderly. J Neurooncol. 2007;85(2):207–11. PubMedCrossRef

29.

Bayraktar S, Bayraktar UD, Ramos JC, Stefanovic A, Lossos IS. Primary CNS lymphoma in HIV positive and negative patients: comparison of clinical characteristics, outcome and prognostic factors. J Neurooncol. 2011;101(2):257–65. PubMedCrossRef

30.

Gonzalez-Aguilar A, Soto-Hernandez JL. The management of primary central nervous system lymphoma related to AIDS in the HAART era. Curr Opin Oncol. 2011;23:648–53. PubMedCrossRef

31.

Abla O, Weitzman S, Blay JY, et al. Primary CNS lymphoma in children and adolescents: a descriptive analysis from the international primary CNS lymphoma collaborative group (IPCG). Clin Cancer Res. 2011;15:346–52. CrossRef

Titel: Primary central nervous system lymphoma: update and current approach
Autor:: M.D. Lauren E. Abrey
Publikationsdatum: 01.09.2012
DOI: https://doi.org/10.1007/s12254-012-0045-9
Verlag: Springer Vienna
Zeitschrift: memo - Magazine of European Medical Oncology An International Journal for Oncology and Haematology Professionals
Ausgabe 3/2012
Print ISSN: 1865-5041
Elektronische ISSN: 1865-5076

Springer Medizin Österreich

Tipp

Weitere Artikel dieser Ausgabe durch Wischen aufrufen

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Sie möchten Zugang zu diesem Inhalt erhalten? Dann informieren Sie sich jetzt über unsere Produkte:

Abo für kostenpflichtige Inhalte

Weitere Artikel der Ausgabe 3/2012

Follow-up care for head and neck cancer patients

ASH 2011—Hodgkin’s disease and the high grade lymphomas

Update on molecular and genetic alterations in adult medulloblastoma

New developments in MDS

Sorafenib in thyroid cancer—a retrospective case series

Carcinomatous meningitis